RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature

RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature

Abstract Patients with epidermal growth factor receptor and anaplastic lymphoma kinase positive non-small cell lung cancer (NSCLC) generally respond poorly to treatment with immune checkpoint inhibitors such as anti-programmed cell death-1 (PD-1) or anti-programmed cell death ligand-1 (PD-L1) given...

Full description

Bibliographic Details
Main Authors: Sara Baglivo, Vienna Ludovini, Riccardo Moretti, Guido Bellezza, Angelo Sidoni, Fausto Roila, Giulio Metro
Format: Article
Language:English
Published: Adis, Springer Healthcare 2020-05-01
Series:Oncology and Therapy
Subjects:
Hyper-progressive disease
Immunotherapy
Non-small cell lung cancer
PD-L1 ≥ 50%
Pembrolizumab
RET
Online Access:https://doi.org/10.1007/s40487-020-00116-2

Internet

https://doi.org/10.1007/s40487-020-00116-2

Similar Items